Europeiska unionen - svenska - EMA (European Medicines Agency)

gedeon richter plc. - follitropin alfa - anovulation - könshormoner och modulatorer av könsorganen, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. i kliniska prövningar dessa patienter definierades av en endogen serum lh nivå < 1. 2 ie / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ibsa farmaceutici italia s.r.l. - koriongonadotropin (humant urin) - pulver och vätska till injektionsvätska, lösning - 5000 ie - koriongonadotropin (humant urin) 5000 ie aktiv substans; laktosmonohydrat hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatiska neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiska neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

novalon s.a. - tibolon - tablett - 2,5 mg - tibolon 2,5 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ibsa farmaceutici italia s.r.l. - menotropin - pulver och vätska till injektionsvätska, lösning - 75 ie - menotropin 75 ie aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ibsa farmaceutici italia s.r.l. - menotropin - pulver och vätska till injektionsvätska, lösning - 150 ie - menotropin 150 ie aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ferring läkemedel ab - menotropin - injektionsvätska, lösning i förfylld injektionspenna - 1200 ie - menotropin 1200 ie aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ferring läkemedel ab - menotropin - injektionsvätska, lösning i förfylld injektionspenna - 600 ie - menotropin 600 ie aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ibsa farmaceutici italia s.r.l. - menotropin - pulver och vätska till injektionsvätska, lösning - 900 ie - menotropin 900 ie aktiv substans; laktosmonohydrat hjälpämne